%PDF-1.4
%
49 0 obj
<>
endobj
46 0 obj
<>
endobj
99 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-07-08T18:54:01Z
2024-03-29T06:04:27-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-29T06:04:27-07:00
application/pdf
Heather
2002-524.aug
uuid:1aaa7475-1dd2-11b2-0a00-da0827fd5800
uuid:1aaa7477-1dd2-11b2-0a00-6a0000000000
endstream
endobj
35 0 obj
<>
endobj
36 0 obj
<>
endobj
50 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 21 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 23 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 25 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 27 0 R/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 29 0 R/Type/Page>>
endobj
117 0 obj
[121 0 R]
endobj
118 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.0625 Tw 10 0 0 10 54 713.1616 Tm
[(considering the high NPV)128.8 (. )17.7 (This ef)17.7 (fect is accentuated in the)]TJ
0.02499 Tw 0 -1.2 TD
(subgroup of IgM-RF negative patients. )Tj
/T1_1 1 Tf
0 Tw 0.275 -2.4 Td
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 61 667.1616 Tm
[(1.)-875.1 (van der Heijde DM, van Leeuwen MA, van Riel PLCM, et al.)]TJ
1.675 -1.25 Td
(Biannual radiographic assessments of hands and feet in a three-year)Tj
0 -1.25 TD
(prospective followup of patients with early rheumatoid arthritis.)Tj
T*
(Arthritis Rheum 1992;35:26-32.)Tj
-1.675 -1.25 Td
[(2.)-875.1 (Hulsmans HMJ, Jacobs JWG, van der Heijde DMFM, van )54.8 (Albada)]TJ
1.675 -1.25 Td
[(Kuipers GA, Schenk )36.8 (Y)128.9 (, Bijlsma JW)91.7 (. )17.7 (The course of radiologic)]TJ
T*
[(damage during the first six years of rheumatoid arthritis. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 2000;43:1927-40.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(3.)-875.1 (Boers M, )17.7 (V)110.8 (erhoeven )54.8 (AC, Markusse HM, et al. Randomised)]TJ
1.675 -1.25 Td
(comparison of combined step-down prednisolone, methotrexate and)Tj
T*
(sulphasalazine with sulphasalazine alone in early rheumatoid)Tj
T*
[(arthritis. )17.7 (The Lancet 1997;350:309-18.)]TJ
-1.675 -1.25 Td
[(4.)-875.1 (Abu-Shakra M, )17.7 (T)69.9 (oker R, Flusser D, et al. Clinical and radiographic)]TJ
1.675 -1.25 Td
(outcomes of rheumatoid arthritis patients not treated with )Tj
T*
[(disease-modifying drugs. )54.8 (Arthritis Rheum 1998;41:1)36.8 (190-5.)]TJ
-1.675 -1.25 Td
[(5.)-875.1 (van der Heijde DMFM, van Riel PL, van Nuver)19.7 (-Zwart IH, Gribnau)]TJ
1.675 -1.25 Td
[(FW)91.7 (, van de Putte LB. Ef)17.7 (fects of hydroxychloroquine and)]TJ
T*
(sulphasalazine on progression of joint damage in rheumatoid)Tj
T*
[(arthritis. )17.7 (The Lancet 1989;1036-8.)]TJ
-1.675 -1.25 Td
[(6.)-875.1 (Arnett FC, Edworthy SM, Bloch DA, et al. )17.7 (The )54.8 (American)]TJ
1.675 -1.25 Td
[(Rheumatism )54.8 (Association 1987 revised criteria for the classification)]TJ
T*
[(of rheumatoid arthritis. )54.8 (Arthritis Rheum 1988;31:315-24.)]TJ
-1.675 -1.25 Td
[(7.)-875.1 (Saraux )54.8 (A, Berthelot JM, Chales G, et al. )54.8 (Ability of the )54.8 (American)]TJ
1.675 -1.25 Td
(College of Rheumatology 1987 criteria to predict rheumatoid)Tj
T*
(arthritis in patients with early arthritis and classification of these)Tj
T*
[(patients two years later)54.8 (. )54.8 (Arthritis Rheum 2001;44:2485-91.)]TJ
-1.675 -1.25 Td
[(8.)-875.1 (V)59.8 (isser H, le Cessie S, )17.7 (V)128.9 (os K, Breedveld FC, Hazes JM. How to)]TJ
1.675 -1.25 Td
[(diagnose rheumatoid arthritis early: )54.8 (A)-220.1 (prediction model for )]TJ
T*
[(persistent \(erosive\) arthritis. )54.8 (Arthritis Rheum 2002;46:357-65.)]TJ
-1.675 -1.25 Td
[(9.)-875.1 (Jansen LMA, van Schaardenbur)17.7 (g D, van der Horst Bruinsma IE,)]TJ
1.675 -1.25 Td
[(Dijkmans BA. One year outcome of undif)17.7 (ferentiated polyarthritis.)]TJ
0 Tc T*
(Ann Rheum Dis 2002;61:700-3.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(10.)-875.1 (Leigh JP)110.7 (, Fries JF)79.7 (. Predictors of disability in a longitudinal sample)]TJ
2.175 -1.25 Td
[(of patients with rheumatoid arthritis. )54.8 (Ann Rheum Dis 1992;)]TJ
0 Tc 0 Tw T*
(51:581-7.)Tj
-0.00011 Tc 0.02499 Tw -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Eberhardt KB, Fex E. Functional impairment and disability in early)]TJ
2.1381 -1.25 Td
(rheumatoid arthritis \321 development over 5 years. J Rheumatol)Tj
0 Tc 0 Tw T*
(1995;22:1037-42.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(12.)-875.1 (van der Heijde DMFM, van Riel PLCM, van Leeuwen MA, van \324t)]TJ
2.175 -1.25 Td
(Hof MA, van Rijswijk MH, van de Putte LBA. Prognostic factors)Tj
T*
(for radiographic damage and physical disability in early rheumatoid)Tj
T*
[(arthritis. )54.8 (A)-220.1 (prospective followup study of 147 patients. )]TJ
T*
(Br J Rheumatol 1992;31:519-25.)Tj
-2.175 -1.25 Td
[(13.)-875.1 (Eberhardt KB, R)39.7 (ydgren LC, Pettersson H, )17.7 (W)79.9 (ollheim F)73.9 (A. Early)]TJ
2.175 -1.25 Td
(rheumatoid arthritis \321 onset, course, and outcome over 2 years.)Tj
T*
(Rheumatol Int 1990;10\(4\):135-142.)Tj
-2.175 -1.25 Td
[(14.)-875.1 (van Zeben D, Hazes JM, Zwinderman )54.8 (AH, )17.7 (V)110.8 (andenbroucke JP)110.8 (,)]TJ
2.175 -1.25 Td
(Breedveld FC. Factors predicting outcome of rheumatoid arthritis:)Tj
T*
(results of a followup study [published erratum appears in )Tj
T*
(J Rheumatol 1993 Dec;20:2179] [see comments]. J Rheumatol)Tj
0 Tc 0 Tw T*
(1993;20:1288-96.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(15.)-875.1 (van der Heide )54.8 (A, Remme CA, Hofman DM, Jacobs JW)91.7 (, Bijlsma)]TJ
2.175 -1.25 Td
[(JW)91.7 (. Prediction of progression of radiologic damage in newly )]TJ
T*
[(diagnosed rheumatoid arthritis. )54.8 (Arthritis Rheum 1995;38:1466-74.)]TJ
-2.175 -1.25 Td
[(16.)-875.1 (van der Heijde DM, van Leeuwen MA, van Riel PLCM, et al.)]TJ
2.175 -1.25 Td
(Biannual radiographic assessments of hands and feet in a three-year)Tj
33 74.671 Td
(prospective followup of patients with early rheumatoid arthritis.)Tj
T*
(Arthritis Rheum 1992;35:26-32.)Tj
-2.175 -1.25 Td
[(17.)-875.1 (Matsuda )36.8 (Y)128.9 (,)-0.1 ( )36.8 (Y)99.8 (amanaka H, Higami K, Kashiwazaki S. )17.7 (T)35 (ime lag)]TJ
2.175 -1.25 Td
(between active joint inflammation and radiological progression in)Tj
T*
(patients with early rheumatoid arthritis. J Rheumatol 1998;)Tj
0 Tc 0 Tw T*
(25:427-32. )Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(18.)-875.1 (van-Leeuwen MA, van-Rijswijk MH, Sluiter )17.7 (WJ, et al. Individual)]TJ
2.175 -1.25 Td
(relationship between progression of radiological damage and the)Tj
T*
[(acute phase response in early rheumatoid arthritis. )17.7 (T)69.9 (owards )]TJ
T*
(development of a decision support system. J Rheumatol)Tj
0 Tc 0 Tw T*
(1997;24:20-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(19.)-875.1 (Kroot EJA, de Jong BA)79.7 (W)91.8 (, van Leeuwen MA, et al. )17.7 (The prognostic)]TJ
2.175 -1.25 Td
(value of anti-cyclic citrullinated peptide antibody in patients with)Tj
T*
[(recent-onset rheumatoid arthritis. )54.8 (Arthritis Rheum 2000;43:1831-5.)]TJ
-2.175 -1.25 Td
[(20.)-875.1 (Nienhuis RLF)79.7 (, Mandema E. )54.8 (A)-220.1 (new serum factor in patients with)]TJ
2.175 -1.25 Td
[(rheumatoid arthritis, the antiperinuclear factor)54.8 (. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(1964;23:302-5.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(21.)-875.1 (Hoet RM, Boerbooms )54.8 (AM, )54.8 (Arends M, Ruiter DJ, van )17.7 (V)110.8 (enrooij )17.7 (WJ.)]TJ
2.175 -1.25 Td
[(Antiperinuclear factor)39.7 (, a marker autoantibody for rheumatoid)]TJ
T*
(arthritis: colocalisation of the perinuclear factor and profilaggrin.)Tj
0 Tc T*
[(Ann Rheum Dis 1991;50:61)36.9 (1-8.)]TJ
-0.00011 Tc -0.0298 Tw -2.175 -1.25 Td
[(22.)-875.1 (W)79.9 (estgeest AA, )-54.8 (Boerbooms AM, )-54.9 (Jongmans )-54.9 (M, )-37.1 (V)110.8 (andenbroucke )-54.8 (JP)110.7 (,)]TJ
0.02499 Tw 2.175 -1.25 Td
[(V)59.8 (ierwinden G, van der Putte LB. )54.8 (Antiperinuclear factor: indicator)]TJ
T*
(of more severe disease in seronegative rheumatoid arthritis. )Tj
T*
(J Rheumatol 1987;14:893-7.)Tj
-2.175 -1.25 Td
[(23.)-875.1 (van Jaarsveld CHM, ter Bor)17.7 (g EJ, Jacobs JWG, et al. )17.7 (The prognostic)]TJ
2.175 -1.25 Td
[(value of the antiperinuclear factor)39.7 (, anti-citrullinated peptide )]TJ
T*
(antibodies and rheumatoid factor in early rheumatoid arthritis. Clin)Tj
T*
(Exp Rheumatol 1999;17:689-97.)Tj
-2.175 -1.25 Td
[(24.)-875.1 (Schellekens GA, )17.7 (V)59.8 (isser H, de Jong BA)79.7 (W)91.9 (, et al. )17.7 (The diagnostic)]TJ
2.175 -1.25 Td
(properties of rheumatoid arthritis antibodies recognizing a cyclic)Tj
T*
[(citrullinated peptide. )54.8 (Arthritis Rheum 2000;43:155-63. )]TJ
-2.175 -1.25 Td
[(25.)-875.1 (Jansen LMA, van der Horst Bruinsma IE, van Schaardenbur)17.7 (g D,)]TJ
2.175 -1.25 Td
[(van de Stadt RJ, de Koning MHMT)73.9 (, Dijkmans BA. Rheumatoid)]TJ
T*
[(factor and antibodies to cyclic citrullinated peptide dif)17.7 (ferentiate)]TJ
T*
[(rheumatoid arthritis from undif)17.7 (ferentiated polyarthritis in patients)]TJ
T*
(with early arthritis. J Rheumatol 2002;29:2074-6. )Tj
-2.175 -1.25 Td
[(26.)-875.1 (Prevoo ML, van \324t Hof M, Kuper HH, van Leeuwen MA, van de)]TJ
2.175 -1.25 Td
(Putte LB, van Riel PL. modified disease activity scores that include)Tj
T*
[(twenty-eight joint counts: development and validation. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1995;38:44-8.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(27.)-875.1 (Bijlsma JW)91.7 (, Oude Heuvel CHB, Zaalber)17.7 (g )54.8 (A. Development and)]TJ
2.175 -1.25 Td
(validation of the Dutch questionnaire capacities of daily life \(VDF\))Tj
T*
(for patients with rheumatoid arthritis. J Rehabil Sci 1990;3:71-4.)Tj
-2.175 -1.25 Td
[(28.)-875.1 (Bruynesteyn K, van der Heijde D, Boers M, et al. Determination of)]TJ
2.175 -1.25 Td
[(the minimal clinically important dif)17.7 (ference in rheumatoid arthritis)]TJ
T*
(joint damage of the Sharp/van der Heijde and Larsen/Scott scoring)Tj
T*
(methods by clinical experts and comparison with the smallest)Tj
T*
[(detectable dif)17.7 (ference. )54.8 (Arthritis Rheum 2002;46:913-20.)]TJ
-2.175 -1.25 Td
[(29.)-875.1 (Hakala M, Niemine P)110.7 (, Koivisto O. More evidence from a )]TJ
2.175 -1.25 Td
(community based series of better outcome in rheumatoid arthritis.)Tj
T*
[(Data on the ef)17.7 (fect of multidisciplinary care on the retention of )]TJ
T*
[(functional ability)64.8 (. J Rheumatol 1994;21:1432-7.)]TJ
-2.175 -1.25 Td
[(30.)-875.1 (Goldbach-Mansky R, Lee J, McCoy )54.8 (A, et al. Rheumatoid arthritis)]TJ
2.175 -1.25 Td
(associated autoantibodies in patients with synovitis of recent onset.)Tj
T*
(Arthritis Res 2000;2:236-43.)Tj
-2.175 -1.25 Td
[(31.)-875.1 (Scott DL, Pugner K, Kaarela K, et al. )17.7 (The links between joint)]TJ
2.175 -1.25 Td
(damage and disability in rheumatoid arthritis. Rheumatology)Tj
0 Tc 0 Tw T*
(2000;39:122-33.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.5 35.9844 Tm
[(Jansen, et al: )17.7 (Anti-CCP)-257.3 (in early arthritis)]TJ
0 Tc 0 Tw 60.9375 -0.0313 Td
(1695)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.09 396.48 -10.84 re
f*
0.5 w
109.22 59.09 396.48 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
29 0 obj
<>stream
8;Z\6JSp0,#ikr7OPa4'PIB7dT(g_\9-fF:'0.J;kl0:Os2kc4gJ9_Pq0)f(Z/;J"
9e7qA,T!X+XsWS/(gC%NDSNoAp3ZVJcPl+ZYNNW_Qltf"YB"^bi\!BGo0V/eJ/@#E
O`\[9)1#KKG"A6]:>^$Z!o6><;l3,TQ">Aj^-IP)1^7oL,:tL!H$#4_2K`:R?WW8Rj9V`^,_^oUY.N
V]rg*m''Vg2rOTO(jWqs[5//q"/deB)GI;("%3VU7!loh"q5;k
E>2UC72%B%KH_6QV5`I)R0e$FA0SBWi+f;In^0:qZn+@P5nB>rpF5*SIA/Dd)dp.o
Nma\$\RH27tX`f'R)M
?];#Q~>
endstream
endobj
33 0 obj
[/Indexed/DeviceRGB 255 32 0 R]
endobj
32 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
57 0 obj
<>
endobj
13 0 obj
<>
endobj
52 0 obj
<>
endobj
88 0 obj
<>
endobj
104 0 obj
<>
endobj
53 0 obj
<>
endobj
80 0 obj
<>stream
HT{PSg˽h&ZvTDKEADE^RQb$@#G#"X>jQQo֎֩.n;g7|7ߙs`8;,KDqXu96\e;it,f18͵eܙI~!*-}ͮ;tm[{rwe81I.\^-yW> xpR&Id{vHRiqrQP蓜,|S+dtk
cX&DBNaxTL }q{IӄbkL/'"oվy|6'hC[lEᘷi7θgmTS /mҋ&˛.3؇_:p\ۑe3gvZ+YM MgN_n?ڧ4$e&!y,C%EOa zC*wljԤ0::&T-f|uW&*9fS43ۑ~R|RW= 4{}OO
f/js.x&@d;4VS.MP֟=yF{`-m3$"9F佺